Back

LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering (1) Lipids ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Kunal Mahajan

Himachal Heart Institute, Mandi (India)

6 More presentations in this session

Presentation thumbnail
Bridging the gap: real-world eligibility for lipoprotein(a)-targeted therapies in chronic and acute coronary syndrome
Doctor E. Steinacher (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Association of LDL-C/ApoB ratio with pathogenic variants in familial hypercholesterolemia
Doctor F. Wollmann (Wien, AT)
Abstract Slides Video
Presentation thumbnail
Real-world efficacy and tolerability of lipid-lowering therapy in children with monogenic familial hypercholesterolemia in primary care
Mr R. Schmieder (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Association of apolipoprotein B and lipoprotein(a) with severe atherosclerotic cardiovascular disease in patients with acute coronary syndrome: the modifying effect of prior lipid-lowering therapy.
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides Video
Presentation thumbnail
Elective coronary revascularisation represents an unutilised opportunity to optimise lipid management: results from a multicentre observational cohort
Miss M. van den Bogaart (Amsterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid lowering (1)

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Exploring residual cardiovascular risk beyond LDL cholesterol in patients with acute destabilisation of known significant atherosclerosis
30 August 2025
thumbnail
Congress Presentation
Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)
30 August 2026
thumbnail
Congress Presentation
Transient surge, persistent risk: longitudinal changes in lipoprotein(a) following acute coronary syndrome
28 August 2026
thumbnail
Congress Presentation
Case 2 - a patient with premature atherosclerotic cardiovascular disease but well-controlled LDL-C - from genetic risk to clinical decision-making
23 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources